Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 1729

1.

APRIL and BCMA promote human multiple myeloma growth, chemoresistance, and immunosuppression in the bone marrow microenvironment.

Tai YT, Acharya C, An G, Moschetta M, Zhong MY, Feng X, Cea M, Cagnetta A, Wen K, van Eenennaam H, van Elsas A, Qiu L, Richardson P, Munshi N, Anderson KC.

Blood. 2016 Apr 28. pii: blood-2016-01-691162. [Epub ahead of print]

PMID:
27127303
2.

Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.

Moreau P, Masszi T, Grzasko N, Bahlis NJ, Hansson M, Pour L, Sandhu I, Ganly P, Baker BW, Jackson SR, Stoppa AM, Simpson DR, Gimsing P, Palumbo A, Garderet L, Cavo M, Kumar S, Touzeau C, Buadi FK, Laubach JP, Berg DT, Lin J, Di Bacco A, Hui AM, van de Velde H, Richardson PG; TOURMALINE-MM1 Study Group.

N Engl J Med. 2016 Apr 28;374(17):1621-34. doi: 10.1056/NEJMoa1516282.

PMID:
27119237
3.

A novel hypoxia-selective epigenetic agent RRx-001 triggers apoptosis and overcomes drug resistance in multiple myeloma cells.

Das DS, Ray A, Das A, Song Y, Oronsky B, Richardson P, Scicinski J, Chauhan D, Anderson KC.

Leukemia. 2016 Apr 27. doi: 10.1038/leu.2016.96. [Epub ahead of print]

PMID:
27118403
4.

Defibrotide for Treatment of Severe Veno-Occlusive Disease in Pediatrics and Adults: An Exploratory Analysis Using Data from the CIBMTR.

Strouse C, Richardson P, Prentice G, Korman S, Hume R, Nejadnik B, Horowitz MM, Saber W.

Biol Blood Marrow Transplant. 2016 Apr 19. pii: S1083-8791(16)30030-1. doi: 10.1016/j.bbmt.2016.04.011. [Epub ahead of print]

PMID:
27108694
5.

A novel alkylating agent Melflufen induces irreversible DNA damage and cytotoxicity in multiple myeloma cells.

Ray A, Das DS, Song Y, Nordström E, Gullbo J, Richardson PG, Chauhan D, Anderson KC.

Br J Haematol. 2016 Apr 20. doi: 10.1111/bjh.14065. [Epub ahead of print]

PMID:
27098276
6.

The Future of Myeloma Therapy: One Size Does Not Fit All.

Richardson PG.

J Oncol Pract. 2016 Apr;12(4):295-6. doi: 10.1200/JOP.2016.011502. No abstract available.

PMID:
27072382
7.

Endoscopic Debridement for Treatment of Chronic Plantar Fasciitis: An Innovative Technique and Prospective Study of 46 Consecutive Patients.

Cottom JM, Maker JM, Richardson P, Baker JS.

J Foot Ankle Surg. 2016 Apr 5. pii: S1067-2516(16)00073-9. doi: 10.1053/j.jfas.2016.02.005. [Epub ahead of print]

PMID:
27066869
8.

Dual inhibition of oncogenic targets for B-cell malignancies.

Richardson PG.

Lancet Oncol. 2016 Mar 31. pii: S1470-2045(16)00109-1. doi: 10.1016/S1470-2045(16)00109-1. [Epub ahead of print] No abstract available.

PMID:
27049458
9.

Phase 1 study of marizomib in relapsed or relapsed and refractory multiple myeloma; NPI 0052 101 Part 1.

Richardson PG, Zimmerman TM, Hofmeister CC, Talpaz M, Chanan-Khan AA, Kaufman JL, Laubach JP, Chauhan D, Jakubowiak AJ, Reich S, Trikha M, Anderson KC.

Blood. 2016 Mar 23. pii: blood-2015-12-686378. [Epub ahead of print]

PMID:
27009059
10.

Myeloma cell dynamics in response to treatment supports a model of hierarchical differentiation and clonal evolution.

Tang M, Zhao R, van de Velde H, Tross JG, Mitsiades CS, Viselli S, Neuwirth R, Esseltine DL, Anderson KC, Ghobrial IM, San Miguel J, Richardson PG, Tomasson MH, Michor F.

Clin Cancer Res. 2016 Mar 22. pii: clincanres.2793.2015. [Epub ahead of print]

PMID:
27006493
11.

Manipulating walking path configuration influences gait variability and six-minute walk test outcomes in older and younger adults.

Barnett CT, Bisele M, Jackman JS, Rayne T, Moore NC, Spalding JL, Richardson P, Plummer B.

Gait Posture. 2016 Feb;44:221-6. doi: 10.1016/j.gaitpost.2015.12.022. Epub 2015 Dec 23.

PMID:
27004662
12.

International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment.

Dimopoulos MA, Sonneveld P, Leung N, Merlini G, Ludwig H, Kastritis E, Goldschmidt H, Joshua D, Orlowski RZ, Powles R, Vesole DH, Garderet L, Einsele H, Palumbo A, Cavo M, Richardson PG, Moreau P, San Miguel J, Rajkumar SV, Durie BG, Terpos E.

J Clin Oncol. 2016 May 1;34(13):1544-57. doi: 10.1200/JCO.2015.65.0044. Epub 2016 Mar 14.

13.

The impact on hospital resource utilisation of treatment of hepatic encephalopathy with rifaximin-α.

Orr JG, Currie CJ, Berni E, Goel A, Moriarty KJ, Sinha A, Gordon F, Dethier A, Dillon J, Clark K, Richardson P, Middleton P, Patel V, Shawcross D, Preedy H, Aspinall RJ, Hudson M.

Liver Int. 2016 Mar 7. doi: 10.1111/liv.13111. [Epub ahead of print]

PMID:
26950766
14.

Risk of Hepatocellular Carcinoma after Sustained Virologic Response in Veterans with HCV-infection.

El-Serag HB, Kanwal F, Richardson P, Kramer J.

Hepatology. 2016 Mar 4. doi: 10.1002/hep.28535. [Epub ahead of print]

PMID:
26946190
15.

Conformational Studies and Atropisomerism Kinetics of the ALK Clinical Candidate Lorlatinib (PF-06463922) and Desmethyl Congeners.

Elleraas J, Ewanicki J, Johnson TW, Sach NW, Collins MR, Richardson PF.

Angew Chem Int Ed Engl. 2016 Mar 7;55(11):3590-5. doi: 10.1002/anie.201509240. Epub 2016 Feb 16.

PMID:
26880581
16.

How Well Do Inexpensive, Portable Pulse Oximeter Values Agree with Arterial Oxygenation Saturation in Acutely Ill Patients?

Jones M, Olorvida E, Monger K, Yarborough V, Bennetts H, Harris D, Keith C, Boggs L, Firrincieli B, Ingram L, Richardson P, Locklear D, Sigmon S, Lewis J, Murphy J.

Medsurg Nurs. 2015 Nov-Dec;24(6):391-6.

PMID:
26863701
17.

Multiple Myeloma in Pregnancy-A Review of the Literature and a Case Series.

Jurczyszyn A, Olszewska-Szopa M, Vesole AS, Vesole DH, Siegel DS, Richardson PG, Paba-Prada C, Callander NS, Huras H, Skotnicki AB.

Clin Lymphoma Myeloma Leuk. 2016 Mar;16(3):e39-45. doi: 10.1016/j.clml.2015.11.020. Epub 2015 Dec 2.

PMID:
26847816
18.

Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure.

Richardson PG, Riches ML, Kernan NA, Brochstein JA, Mineishi S, Termuhlen AM, Arai S, Grupp SA, Guinan EC, Martin PL, Steinbach G, Krishnan A, Nemecek ER, Giralt S, Rodriguez T, Duerst R, Doyle J, Antin JH, Smith A, Lehmann L, Champlin R, Gillio A, Bajwa R, D'Agostino RB Sr, Massaro J, Warren D, Miloslavsky M, Hume RL, Iacobelli M, Nejadnik B, Hannah AL, Soiffer RJ.

Blood. 2016 Mar 31;127(13):1656-65. doi: 10.1182/blood-2015-10-676924. Epub 2016 Jan 29.

19.

TAK-228 (formerly MLN0128), an investigational oral dual TORC1/2 inhibitor: A phase I dose escalation study in patients with relapsed or refractory multiple myeloma, non-Hodgkin lymphoma, or Waldenström's macroglobulinemia.

Ghobrial IM, Siegel DS, Vij R, Berdeja JG, Richardson PG, Neuwirth R, Patel CG, Zohren F, Wolf JL.

Am J Hematol. 2016 Jun;91(4):400-5. doi: 10.1002/ajh.24300.

20.

Clinical utility of C-terminal telopeptide of type 1 collagen in multiple myeloma.

Ting KR, Brady JJ, Hameed A, Le G, Meiller J, Verburgh E, Bayers C, Benjamin D, Anderson KC, Richardson PG, Dowling P, Clynes M, Fitzgibbon MC, O'Gorman P.

Br J Haematol. 2016 Apr;173(1):82-8. doi: 10.1111/bjh.13928. Epub 2016 Jan 20.

PMID:
26787413
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk